INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
NEW HAVEN, Conn., April 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.  (Nasdaq:ACHN) today announced initiation of patient dosing in a Phase 2 open-label study of ACH-4471, Achillion's first orally-administered, small molecule factor D inhibitor, for patients with paroxysmal
View HTML
Toggle Summary USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No.
View HTML
Toggle Summary Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London
Three-year study commenced to include up to 400 patients Natural history studies track course of a disease over time; can inform and support development and approval of new treatments for patients C3 glomerulopathy currently has no cure or approved treatment; affects about 8,000 people across
View HTML
Toggle Summary Achillion Reports 2016 Fourth Quarter and Year-End Financial Results
Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017 Expanding complement platform includes internally discovered next-generation oral factor D inhibitors with the goal of advancing at least one into
View HTML
Toggle Summary Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference
NEW HAVEN, Conn., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Leerink Partners 6 th Annual Global Healthcare Conference on
View HTML
Toggle Summary Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
NEW HAVEN, Conn., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.  (Nasdaq:ACHN) today announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to
View HTML
Toggle Summary Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.  (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this important emerging area and demonstrates the potential advantage of factor D inhibitors like the company's
View HTML
Toggle Summary Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV
- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the treatment of chronic HCV - NEW HAVEN, Conn., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Achillion
View HTML
Toggle Summary Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.  (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA, December 3 - 6, 2016.  "The data
View HTML
Toggle Summary Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016 Achillion's phase I MAD study with oral factor D inhibitor ACH-4471 ongoing; strong complement inhibition observed in in vivo and ex vivo assays Company advancing
View HTML